Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM0237 in Advanced Solid Tumors
NCT05781360Phase 1Terminated
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Mar 2023
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, open-label trial of SIM0237 in solid tumor (2 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Incidence and nature of Dose-Limiting Toxicity at 18 months, Percentage of participants experiencing treatment-emergent adverse events at 18 months and 2 more. Started Mar 2023; status: terminated.
02
Drugs
SIM0237
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05781360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05781360.